<DOC>
	<DOCNO>NCT02365506</DOCNO>
	<brief_summary>This study evaluate effect oral eleclazine ( GS-6615 ) QTc interval , safety , tolerability adult long QT2 syndrome .</brief_summary>
	<brief_title>Effect Eleclazine QT , Safety , Tolerability Adults With Long QT2 Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<criteria>Individuals establish diagnosis LQT2 ( genotype testing ) Mean ( triplicate ) QTc interval ≥ 480 msec least four seven time point , determine standard 12lead ECG , screen Known mutation associate LQT1 LQT3 Known suspect history seizure epilepsy History heart failure define New York Heart Association ( NYHA ) Class IV and/or know left ventricular ejection fraction ( EF ) ≤ 45 % Body mass index ( BMI ) ≥ 36 kg/m^2 screen Severe renal impairment screening ( define estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m^2 , use 4 Variable Modification Diet Renal Disease ( MDRD ) equation ) , determine study center Abnormal liver function test screen , define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal ( ULN ) , total bilirubin &gt; 1.5 x ULN An aborted cardiac arrest ( ACA ) , implantable cardioverterdefibrillator ( ICD ) implantation , syncopal episode , appropriate ICD therapy within 3 month prior screen Any condition circumstance opinion investigator would preclude compliance study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Congenital Long QT Syndrome</keyword>
	<keyword>LQTS</keyword>
	<keyword>Long QT2 Syndrome</keyword>
	<keyword>LQT2</keyword>
	<keyword>Sudden Cardiac Death</keyword>
</DOC>